Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes

Diabetes Clinical Trial

— GLUCONEO  

Official title:

Devenir au Long Cours de la Cellule bêta Chez Les Adultes Porteurs d'Anomalies génétiques à l'Origine du Diabète Néonatal

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02072551
• Other study ID #: GLUCONEO
• Status: Active, not recruiting
• Phase: N/A
• First received: November 4, 2013
• Last updated: April 15, 2016
• Start date: December 2012
• Est. completion date: December 2016

Study information

• Verified date: April 2016
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Observational

Clinical Trial Summary

The main objective of this study is to evaluate Beta cells in patients with a neonotal diabetes linked to a genetic abnormality Metabolic caracteristics will described using a transversal cohort study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 17
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age : 18 à 65 year

• diabetic patient with a neonatal diabetis (before 1 year old) and need for insuline or patient with a relative having neonatal diabetis

Exclusion Criteria:

Diabète induit (médicaments - ex corticoïdes) ou syndromique

• infection

• cancer

• pegnancy

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Diabetes

Locations

Country	Name	City	State
France	Hopital Siant-louis	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean insulin secretion output		Week after inclusion	No
Secondary	insulin secretion outout after arginine perfusion		during hospitalisation (3 days)	No
Secondary	sensitivity to insulin		during hospitalisation (3 days)	No
Secondary	glucago secretion output		during hospitalisation (3 days)	No